Advancing Healthcare: From Testing to Treatment

On average, only 25 new experimental drugs were approved by the FDA’s Center for Drug Evaluation and Research (CDER) every year during the past decade. Taking more than 10 years to go from testing to treatment, the healing properties of these drugs help countless numbers of patients, sometimes providing life-changing and lifesaving results.
Addressing Declining Vaccination Rates

A “vaccination gap” has resulted in fewer children receiving the recommended immunizations, and diseases that were once considered all but eliminated are reemerging.
Safe Medicine: A Shared Responsibility

FFF Enterprises takes a “safety first” approach when it comes to business best practices for distributing fragile biologics and transport-sensitive vaccines.
Leading Innovation and Supply Chain Safety

As president and CEO of TraceLink,Inc., Shabbir Dahod leads a visionary team that helps companies meet the complex requirements of the Drug Supply Chain Security Act.
The Growth of the Plasma Market

In this annual plasma-themed issue of BioSupply Trends Quarterly, we take a critical look at the current plasma market, especially issues of supply and demand.
Healthcare Solutions: Peering Into the Future

As we peer into the not-too-distant future, is it possible that some of the treatments that seem so innovative today will also be looked back upon as unsophisticated?
Celebrating Five Years of BioSupply Reporting

From a bi-weekly newsletter to an award-winning quarterly magazine, BioSupply Trends Quarterly has grown to be a timely, trustworthy source for biopharmaceutical news.
Helping Healthcare Care for More than 25 Years

As CEO of FFF Enterprises, Inc., Patrick Schmidt takes pride in his company’s success in helping to secure the specialty biopharmaceuticals marketplace over the past 26 years.
Minimizing the Risks of Medicine

A deeper look at major risks in the healthcare industry, including lack of preventative care, inadequate care, adverse drug reactions and counterfeit drugs.
On the Frontlines of Flu Prevention

As U.S. Director of Sales & Marketing, Influenza, Chris Woolway is creating strategic partnerships to address industry challenges.